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We report a recurrent CNOT1 de novo missense mutation, NM_016284.4:c.1603C>T, 
p.(Arg535Cys), resulting in a syndrome of pancreatic agenesis and abnormal forebrain 
development in three individuals and a similar phenotype in mice. CNOT1 is a transcriptional 
repressor which has been suggested as being critical for maintaining embryonic stem cells in a 
pluripotent state. These findings suggest that CNOT1 plays a critical role in pancreatic and 
neurological development and describe a novel genetic syndrome of pancreatic agenesis and 
holoprosencephaly. 
Discovering genes with mutations causal of pancreatic agenesis is crucial to identifying factors 
needed for pancreatic development. To date pathogenic variants in six genes (PTF1A [MIM: 615935], 
PDX1 [MIM: 260370], GATA6 [MIM: 600001], GATA4 [MIM: 600576], HNF1B [MIM: 137920], and 
RFX6 [MIM: 615710]) have been reported to severely affect pancreatic development and result in 
pancreatic agenesis1. Gene discovery in pancreatic agenesis has shown both similarities and marked 
differences between pancreatic development in human and mouse. In both species complete loss of 
function of PTF1A, PDX1 or RFX6 results in pancreatic agenesis. In contrast, whilst haploinsufficiency 
of GATA6 is a common cause of pancreatic agenesis in humans2, in mice Gata6 knockout does not 
result in abnormal pancreatic development3. Knowledge of human pancreatic development is 
essential to guide progress of beta-cell replacement therapy for people with Type 1 diabetes. 
We investigated an international cohort of 107 individuals diagnosed with pancreatic agenesis - 
defined by requiring both endocrine (insulin) and exocrine (pancreatic enzymes) replacement 
therapy within the first 6 months of life - and identified a mutation in a known gene in 98 of them 
(Table S1). To identify de novo mutations in the remaining nine subjects, exome sequencing was 
performed for the probands and both their unaffected parents when available (n=7) (Online 
Methods). 
We identified a heterozygous missense mutation in CNOT1 [MIM: 604917], 
NM_016284.4:c.1603C>T, p.(Arg535Cys), in three individuals with pancreatic agenesis. The variant 
had arisen de novo in two of them and was not present in the DNA sample from the 3rd individual’s 
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father (maternal sample was not available for testing) (Figure 1A, Tables S2 and S3). We confirmed 
these results by Sanger sequencing (Online Methods, Figure S1). The p.(Arg535Cys) variant is absent 
from dbSNP138, DECIPHER and GnomAD and affects a residue which is highly conserved across 
species (up to C. Elegans) (Figure 1B). All three in silico prediction tools used (AlignGVGD, PolyPhen2 
and SIFT accessed through AlamutVisual) predicted the variant to have a deleterious effect on 
protein function (Online Methods).  
The three individuals who were heterozygous for the CNOT1 p.(Arg535Cys) variant had strikingly 
similar clinical features (see Supplemental Note). In addition to pancreatic agenesis all three had 
definite (n=2) or possible holoprosencephaly (Figure 1A and Table S4), a disorder in which the 
prosencephalon (forebrain of the embryo) fails to develop into two hemispheres. P01 and P02 (who 
was previously reported by Hilbrands et al4) both had partial/semi-lobar holoprosencephaly, whilst 
P03 has dysmorphic features which could be consistent with holoprosencephaly (prominent central 
incisors and occiput, highly arched palate, and low-set ears) but brain MRI was declined by his 
parents and the diagnosis could not therefore be confirmed. All three individuals had very low birth 
weight (Z-score<-2), likely due to insulin deficiency in the last trimester of pregnancy, when insulin is 
the main foetal growth factor. Consistent with insulin deficiency in utero, the three case subjects all 
developed diabetes very early (2/3 diagnosed at 1 day and one at 13 weeks). P01 and P2 also had 
gallbladder agenesis, a clinical feature frequently associated with pancreatic agenesis. 
The DDD study5 has identified de novo CNOT1 variants in three individuals with developmental delay 
(two missense, p.(Leu2323Phe) and p.(Arg623Trp), and a nonsense (p.(Gln33*)) variant) but none of 
them had holoprosencephaly or diabetes. Since our three case subjects were all heterozygous for 
the same novel missense CNOT1 variant and none of the DDD participants with heterozygous de 
novo CNOT1 variants had pancreatic or neurological structural malformations, we hypothesised that 
a mutation-specific mechanism rather than loss of function was responsible for the phenotype seen 
in our cases. We therefore generated a mouse line harbouring the Cnot1p.(Arg535Cys) mutation using 
CRISPR (Online Methods). 
Heterozygous mice were born at a lower than expected frequency (Table S5), but without an 
obvious phenotype, while homozygosity for the mutation was embryonically lethal. At E14.5, 
embryos were still alive and present at expected Mendelian ratios, and were therefore collected to 
assess their phenotype (Online Methods). Upon dissection, several gross morphological 
abnormalities were apparent in homozygotes, notably exencephaly, eye defects (mostly coloboma) 
and oedema (Figure 2A, 2B, Figure S2 and Table S6).  
High resolution episcopic microscopy (HREM) highlighted a significant reduction in the size of the 
pancreas in homozygous embryos in addition to several other abnormalities (Figure 2C-G, Online 
Methods, DMDD website). The reduction in pancreatic size was found to be predominantly due to a 
smaller dorsal pancreas (Figure 2H, Figure S3). These results provide compelling evidence for the 
role of Cnot1p.(Arg535Cys) in pancreatic development. 
Expression analysis of pancreatic developmental factors on RNA extracted from pancreatic tissue in 
E14.5 wild-type, Cnot1p.(Arg535Cys)/p.(Arg535Cys) and Cnot1p.(Arg535Cys) embryos showed a significant increase 
of Shh expression in homozygous embryos, with decreased expression in Pdx1, Ins, Hnf1b and Ptf1a 
(Figure 3A). No difference in expression was detected for Gata6 (Figure 3A) and Rxra (Figure S4). 
The pancreatic and neurological phenotypes observed in Cnot1p.(Arg535Cys)/p.(Arg535Cys) E14.5 mouse 
embryos are consistent with the pancreatic agenesis and holoprosencephaly observed in the three 
case subjects, confirming that the de novo CNOT1 mutation is indeed the cause of their disease. 
Mice required a homozygous mutation in Cnot1 to display a pancreatic and brain phenotype while a 
heterozygous CNOT1 mutation resulted in the phenotype in three individuals in our cohort. This has 
been described with other pancreatic developmental genes (e.g HNF1B) and supports the hypothesis 
that the early stages of pancreatic development are not identical in mice and humans6.   
The CNOT1 protein has not previously been suggested to have a role in pancreatic development; it is 
known to act both as scaffold of the CCR4-NOT complex and as an independent factor. As such, it 
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mediates transcriptional repression7 and is expressed extremely early during embryonic 
development (E3.5 in the inner cell mass in mice8). In vitro studies have proposed that CNOT1 plays a 
critical role in maintaining human and mice embryonic stem cells in a pluripotent state by inhibiting 
primitive endoderm factors8. CNOT1 expression peaks in undifferentiated human iPS cells compared 
to subsequent stages of in vitro differentiation towards pancreatic endocrine cells9, supporting its 
fundamental role in stem cells. 
The increased expression of Shh in pancreatic tissue extracted from Cnot1p.(Arg535Cys)/p.(Arg535Cys) 
embryos would be consistent with a model in which the CNOT1 p.(Arg535Cys) mutation results in 
embryonic stem cells being maintained in an undifferentiated state through SHH-mediated inhibition 
of differentiation. SHH is a key developmental factor which is known to be crucial for pancreatic and 
brain development. Heterozygous loss of function mutations in SHH cause holoprosencephaly [MIM: 
142945] and studies in both mouse and human embryos have shown that SHH expression needs to 
be repressed in the dorsal foregut endoderm for successful differentiation towards dorsal 
pancreas6,10. A recent study has suggested that the transcription factors Gata4 and Gata6 (mutations 
in which are a cause of pancreatic agenesis) regulate pancreatic endoderm identity by directly 
inhibiting Shh in mice11. It is therefore possible that the p.(Arg535Cys) variant results in CNOT1 
maintaining its inhibition activity on the GATA and other early differentiation factors and, as a 
consequence, SHH expression is not repressed (Figure 3B). Increased expression of Shh and 
decreased expression of Pdx1, Ins, Hnf1b and Ptf1a detected in RNA extracted from pancreatic tissue 
in the E14.5 Cnot1p.(Arg535Cys)/p.(Arg535Cys) embryos would support this hypothesis. However, Gata4 
expression could not be assessed as the assay specificity was too low and Gata6 expression was not 
found to be reduced. It is possible that Gata6 activity is actually inhibited earlier during development 
and then re-activated by a different pathway (Gata6 is needed for development of most 
endodermal-derived organs and heart) or could be inhibited by a different mechanism that does not 
result in reduced expression. The CNOT1 p.(Arg535Cys) mutation also affects neurological 
development in both our cases and mouse embryos. It is possible that this mutation results in 
ectopic SHH expression during brain development. This would be consistent with previous reports of 
Shh ectopic expression impairing midline development12. Another possibility is that the effect of the 
CNOT1 mutation on SHH signalling differs between the brain and the pancreas, resulting in a 
reduced expression in the developing brain and increased expression during pancreatic 
development. Further experiments, ideally on younger embryos and human induced pluripotent 
stem cells, are needed in order to elucidate the mechanism by which the CNOT1 p.(Arg535Cys) 
mutation results in impaired pancreatic and neurological development.  
Our study identifies a spontaneous CNOT1 p.(Arg535Cys) mutation as the genetic cause of a rare 
syndrome of pancreatic agenesis and holoprosencephaly, highlighting a previously unsuspected role 
of CNOT1 as a key factor in both pancreatic and neurological development. This is the 5th gene 
causative of pancreatic agenesis described so far and the first pancreatic agenesis gene which is 
thought to be important for maintaining stem cells’ pluripotency. These findings suggest a new 
mechanism by which impairment of the very early stages of development result in pancreatic 
agenesis and abnormal brain development.  
Declaration of Interests 
The authors declare no competing interests. 
Acknowledgments 
The authors thank the families for participating in this study. We are grateful to Anna-Marie Johnson 
and Benjamin Bunce for their technical assistance and to Dr Jane Ferguson and Dr Joerg Detlev 
Moritz for assistance with the MRI images. We are grateful to Emma Siragher and Monika 
Dabrowska for assistance with embryo dissection, Antonella Galli for advice on embryo work, 
4 
members of the DMDD consortium at the Francis Crick Institute for imaging the embryos, Julia Rose 
for assistance with HREM image analysis, members of the Research Support Facility and Mouse 
Pipelines at the Wellcome Sanger Institute for mouse management and husbandry, Rachel Moore 
and Eleanor Wheeler for help with the mouse statistical analysis, Bill Bottomley for help with mouse 
generation and Elizabeth Wynn for help with genotyping. We would also like to thank Prof Lori 
Sussell for useful discussion on the SHH pathway. 
IB is funded by Wellcome (WT206194). ATH and SE are the recipients of a Wellcome Trust Senior 
Investigator award and ATH is employed as a core member of staff within the NIHR funded Exeter 
Clinical Research Facility and is an NIHR senior investigator. EDF was a Naomi Berrie Fellow in 
Diabetes Research during the study. SEF has a Sir Henry Dale Fellowship jointly funded by the 
Wellcome Trust and the Royal Society (Grant Number: 105636/Z/14/Z). CCW holds a Wellcome Trust 
Intermediate Clinical Fellowship (Grant Number: 105914/Z/14/Z). HH is funded by the Research 
Foundation-Flanders (FWO), the VUB Research Council and Stichting Diabetes Onderzoek Nederland. 
Web Resources 
https://www.omim.org/ 
https://decipher.sanger.ac.uk/ 
https://gnomad.broadinstitute.org 
https://dmdd.org.uk 
References 
1. De Franco, E. & Ellard, S. Genome, Exome, and Targeted Next-Generation Sequencing in
Neonatal Diabetes. Pediatr Clin North Am 62, 1037-53 (2015).
2. Allen, H.L. et al. GATA6 haploinsufficiency causes pancreatic agenesis in humans. Nat Genet
44, 20-22 (2011).
3. Morrisey, E.E. et al. GATA6 regulates HNF4 and is required for differentiation of visceral
endoderm in the mouse embryo. Genes Dev 12, 3579-90 (1998).
4. Hilbrands, R. et al. Pancreas and gallbladder agenesis in a newborn with semilobar
holoprosencephaly, a case report. BMC Med Genet 18, 57 (2017).
5. Firth, H.V. & Wright, C.F. The Deciphering Developmental Disorders (DDD) study. Dev Med
Child Neurol 53, 702-3 (2011).
6. Jennings, R.E. et al. Development of the human pancreas from foregut to endocrine
commitment. Diabetes 62, 3514-22 (2013).
7. Winkler, G.S., Mulder, K.W., Bardwell, V.J., Kalkhoven, E. & Timmers, H.T. Human Ccr4-Not
complex is a ligand-dependent repressor of nuclear receptor-mediated transcription. Embo j
25, 3089-99 (2006).
8. Zheng, X. et al. Cnot1, Cnot2, and Cnot3 maintain mouse and human ESC identity and inhibit
extraembryonic differentiation. Stem Cells 30, 910-22 (2012).
9. van de Bunt, M. et al. Insights into islet development and biology through characterization of
a human iPSC-derived endocrine pancreas model. Islets 8, 83-95 (2016).
10. Apelqvist, A., Ahlgren, U. & Edlund, H. Sonic hedgehog directs specialised mesoderm
differentiation in the intestine and pancreas. Curr Biol 7, 801-4 (1997).
11. Xuan, S. & Sussel, L. GATA4 and GATA6 regulate pancreatic endoderm identity through
inhibition of hedgehog signaling. Development 143, 780-6 (2016).
12. Huang, X., Litingtung, Y. & Chiang, C. Ectopic sonic hedgehog signaling impairs telencephalic
dorsal midline development: implication for human holoprosencephaly. Hum Mol Genet 16,
1454-68 (2007).
5 
Figure Legends: 
Figure 1. Genetic and clinical findings in individuals with pancreatic agenesis. 1A: Partial pedigrees 
and clinical features of the three individuals with the heterozygous CNOT1 p.(Arg535Cys) mutation. 
1B: Conservation of CNOT1 residues 529 to 568 across 10 representative species. Residue p.Arg535 
is highlighted in red. Residues identical to the human CNOT1 protein are highlighted in blue, 
differences are highlighted in grey. 1C Coronal brain MRI of P02 showing absence of the anterior 
interhemispheric fissure (red arrow), fusion of the frontal lobes (orange arrow), absence of frontal 
horns (green arrow), absence of the sylvian fissures (yellow arrow). Splenium of the corpus callosum 
is visible (blue arrow). 1D Post mortem image of P02’s liver (L), spleen (S), and duodenum (D). White 
arrow shows the orthotopic location of the pancreas, which is absent. Dashed arrow indicated site in 
which the absent gallbladder would be expected to be. 
Figure 2. Neurological and pancreatic abnormalities in mouse embryos homozygous for the Cnot1 
p.(Arg535Cys) mutation. 2A Table listing the gross external phenotypes observed in E14.5 embryos. 
Numbers do not add to total as many embryos displayed multiple phenotypes. Significance by 
Fisher’s exact test, assuming an additive model. Exencephaly: p=3.2x10-9, Spina bifida: p=0.027, Eye 
defect: p=5.5x10-8, Oedema: p=2.6x10-7, Midline defect: ns 2B Images showing representative E14.5 
embryos: top shows wildtype embryo, bottom shows embryo homozygous for the CNOT1 
p.(Arg535Cys) mutation with exencephaly and coloboma. 2C and 2E: Coronally sectioned, semi-
transparent 3D volume models of stage matched E14.5 embryos with superimposed models of the 
pancreas of a homozygous (C) and wildtype (E) embryos. 2D. Overlay of extracted surface models of 
the pancreas of a homozygous (blue, magenta), and control (orange, green). 2F, 2G. Coronally 
sectioned solid 3D volume rendered model of the abdomen of the embryos shown in 2C & 2E with 
superimposed pancreas. dp, dorsal pancreas; vp, ventral pancreas; li, liver lobes; s, stomach; sp, 
spleen; k, kidney; g, gonad; bd, bile duct. Scale bars: 1000µm in C, E-G; 500µm in D. 2H: Graph 
showing the volume of the dorsal pancreas of E14.5 embryos in µm3. Blue squares show wildtypes, 
green circles are heterozygotes and red triangles are homozygotes. Data analysed using ANOVA with 
TukeyHSD posthoc test, effect of genotype p=8.85x10-8; post-hoc WT-Hom, p<10-10; Het-Hom, 
p=1.36x10-4, WT-Het, ns. 
Figure 3. Expression data and possible mechanism involving CNOT1 in pancreatic development 3A 
Graphs showing relative expression of genes in the pancreas of E14.5 embryos. Bars show mean +/- 
SE. Data analysed using ANOVA with TukeyHSD posthoc test. Results of posthoc tests shown on 
graphs, * p<0.05, ** p<0.01, *** p<0.001. Shh; effect of genotype p=0.0107. Pdx1; effect of 
genotype p=0.0189. Ins; effect of genotype p=7.03x10-6. Hnf1b; effect of genotype p=0.0294. Ptf1a; 
effect of genotype p=0.00781. Gata6; effect of genotype p=ns. n=4-12 animals per genotype. 3B 
Schematic representation of the proposed role for CNOT1 in pancreatic development.  
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